Skin repair
Skin repair is one of the longest-standing reasons for interest in GHK-Cu, including how damaged or ageing skin recovers and renews itself.
Explore the research →COPPER PEPTIDE & TISSUE BIOLOGY
GHK-Cu
A naturally occurring copper peptide with long-standing research interest around skin quality, collagen, hair and tissue repair.
Skin qualityWound repairCollagen biology
Limited but varied human evidenceTopical and tissue-related research exists, but evidence quality and relevance vary considerably by formulation, route and intended use.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in GHK-Cu?
GHK-Cu is best known as a copper peptide associated with skin renewal, collagen, hair and tissue repair. The attraction is easy to understand: these processes are closely tied to how skin looks and heals, how its structure is maintained and, potentially, how the scalp and hair respond as we age.
Collagen & skin structure
GHK-Cu is frequently associated with collagen and the supporting structure that helps give skin its firmness and resilience.
Explore the research →Skin ageing
Cosmetic interest centres on smoother texture, firmness and the visible changes associated with sun exposure and ageing.
Explore the research →Hair & scalp
GHK-Cu also appears in discussions and products aimed at supporting the scalp and encouraging healthier-looking hair.
Explore the research →THE SCIENCE BIT
A tiny peptide that holds onto copper.
GHK is made from three amino acids: glycine, histidine and lysine. Parts of this short peptide coordinate a copper ion, forming the complex called GHK-Cu. Think of the peptide as a small molecular holder, rather than copper floating freely.
That binding changes how copper participates in local chemistry. Researchers study the complex in collagen, tissue remodelling and skin repair; it is not a proven delivery service that automatically carries copper wherever the body needs it.
See the studies & trials →- GHK
- The three-amino-acid peptide
- Copper ion
- Held in a coordination complex
- Tissue signals
- Collagen and remodelling research
How this connects to the research
Copper binding is established chemistry; outcomes depend on the product and route.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where GHK-Cu connects with the body
These are the tissues and biological systems behind the interest in GHK-Cu.
- Skin
- Dermal cells and collagen.
- Hair follicles
- Scalp and follicle research.
- Repair tissue
- Extracellular-matrix remodelling.
The research behind the interest
Skin repair
Skin repair is one of the longest-standing reasons for interest in GHK-Cu, including how damaged or ageing skin recovers and renews itself.
Laboratory, animal and some human topical studies have explored wound repair, skin appearance and the rebuilding of supporting skin tissue.
Mixed preclinical & human evidenceExplore the studies →Collagen & skin structure
GHK-Cu is frequently associated with collagen and the supporting structure that helps give skin its firmness and resilience.
Laboratory studies suggest effects on genes and repair processes involved in collagen and the surrounding tissue structure.
Mechanistic & preclinical evidenceExplore the studies →Skin ageing
Cosmetic interest centres on smoother texture, firmness and the visible changes associated with sun exposure and ageing.
Some small human studies and product-specific data are encouraging, although the evidence is not strong enough to support every anti-ageing claim made for copper peptides.
Limited human evidenceExplore the studies →Hair & scalp
GHK-Cu also appears in discussions and products aimed at supporting the scalp and encouraging healthier-looking hair.
There are plausible biological reasons for the interest, but strong clinical evidence for meaningful hair regrowth is still limited.
Early / limited evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableEffects of topical copper tripeptide complex on CO2 laser-resurfaced skin ↗
Patients undergoing circumoral CO2 laser skin resurfacing
TopicalPost-procedure skin-care regimenPost-treatment recovery period
Patients were randomized to post-laser skin-care regimens with or without a GHK-Cu-containing copper tripeptide complex.
Patient satisfaction was significantly higher in the GHK-Cu group; the study did not establish broad anti-ageing efficacy.
Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex GHK-Cu ↗
Normal human fibroblasts in culture
In vitro exposureLaboratory study
GHK-Cu produced a dose-dependent increase in several glycosaminoglycan fractions in cultured human fibroblasts.
The findings support a tissue-remodelling mechanism but do not establish a clinical treatment effect.
Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective ↗
Published topical GHK / GHK-Cu research
TopicalLiterature review
The review found strong cellular interest in GHK and GHK-Cu for skin ageing and repair.
It also highlighted the limited amount of modern clinical evidence and unresolved questions around skin permeability and real-world effectiveness.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceEarly
1/5 evidence depth
✓
Clinical efficacyEarly
1/5 evidence depth
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
◇
Safety evidenceEarly
1/5 evidence depth
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
HOW TO READ THESE SCORESDeveloping preclinical evidence · early human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
GHK-Cu research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Skin quality
RESEARCH AREA 02Wound repair
RESEARCH AREA 03Collagen biology
RESEARCH AREA 04Hair & scalp research
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with GHK-Cu
GHK-Cu attracts interest because skin quality, collagen, wound repair and hair health form a coherent story. The most credible practical evidence is topical and product-specific; injectable routines are much less characterised.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Smoother texture and firmer-looking skin
Fine lines, uneven texture and a less resilient-looking complexion drive skincare interest. People want a visible cosmetic improvement, often as part of an existing routine rather than as a stand-alone intervention.
- What makes a report informative
- Comparable photographs of texture and fine lines over time.
- What can muddy the picture
- Moisturisers, retinoids, lighting and product formulation can change the apparent result.
Skin appearance during weight loss
People losing weight may become interested in skin quality or a looser-looking appearance. The hoped-for change is a better-looking skin surface; preventing or reversing substantial loose skin is a much larger claim.
- What makes a report informative
- Texture and appearance separated from changes in body size.
- What can muddy the picture
- Weight loss itself changes contours; skin-firmness reports do not establish prevention of loose skin.
Hair density and less shedding
Hair and scalp interest centres on shedding, thinner areas and a fuller appearance. A convincing account needs to distinguish new growth from styling, reduced breakage or concurrent hair treatments.
- What makes a report informative
- Standardised scalp photographs and the full hair-care history.
- What can muddy the picture
- Minoxidil, finasteride, hair cycles and grooming are important confounders.
Repair and resilience of skin
The tissue-remodelling story also attracts interest in irritated or damaged skin. Cosmetic appearance, wound healing and injected use are different questions with different evidence requirements.
- What makes a report informative
- The exact skin problem and whether the product was topical or injected.
- What can muddy the picture
- Results from a topical formulation do not establish safety or benefit of injectable GHK-Cu.
FROM PUBLIC DISCUSSIONS
Experiences worth looking at
Selected first-hand accounts illustrate the goals and the variation in experience. They are examples, not a representative sample or proof of an effect.
Hair observations during weight loss
A first-hand report connects interest in skin appearance during weight loss with an unexpected perceived hair change. It is an uncontrolled observation.
Read the discussionSkin texture and fine-line questions
A skincare discussion illustrates the desire for cosmetic change and uncertainty about injected GHK-Cu. A question about benefit is not proof of benefit.
Read the discussionPUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Smoother, firmer-looking skin
Human findings & limits
Small topical and post-procedure studies provide limited human support, but formulations and outcomes vary.
Laboratory & animal context
Cell research links GHK-Cu with extracellular-matrix, collagen and repair-related signalling.
What this means: Promising for topical skin research, but broad anti-ageing claims remain ahead of the evidence.
Support for wound and tissue repair
Human findings & limits
Human evidence is mainly product- and procedure-specific rather than a general healing treatment programme.
Laboratory & animal context
Laboratory work supports effects on fibroblasts, matrix biology and repair signalling.
What this means: Biologically credible, with limited direct clinical proof for most everyday uses.
Hair and scalp support
Human findings & limits
Robust controlled evidence for meaningful hair regrowth is limited.
Laboratory & animal context
Copper-peptide and follicle biology offer a rationale, but do not establish a predictable result.
What this means: An active area of interest rather than an established hair-loss treatment.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
COMMUNITY / EDITORIAL EXAMPLE
NOT CLINICAL GUIDANCEFive-day weekly editorial example
Human topical skin-care research does not establish this injectable pattern. Monday to Friday gives the calendar copy five days each week; those particular weekdays are an editable choice.
1Weeks 1–4
1 mgFive days per week · amount each time
2Weeks 5–8
1.5 mgFive days per week · amount each time
3Weeks 9–12
2 mgFive days per week · amount each time
What the figures showInjection under the skin, as described in the example. This copy stops after twelve weeks. Twelve weeks is an example window, not a validated course or storage period.
Use an editable calendar copyReview the amounts, days and stages in the planner before saving. These figures do not establish how long a prepared vial remains usable.Open the calendar planner
Human research is mainly topical and product-specific; there is no validated general injectable GHK-Cu dosing protocol in the evidence set.
PUBLISHED HUMAN RESEARCH
View source ↗Post-CO2-laser topical study ↗
Patients after circumoral CO2 laser resurfacing
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Patients after circumoral CO2 laser resurfacing. Route: Applied to the skin. The study lasted post-treatment recovery period. The figures below describe the research design, not a personal schedule.
| First amount studied | Product-specific topical regimen |
|---|---|
| How often? | As used in the post-procedure skin-care protocol |
| How was it given? | Applied to the skin |
| How long? | Post-treatment recovery period |
See the exact study wording +
Start / initial: Product-specific topical regimen
End / target: Product-specific topical regimen
Frequency: As used in the post-procedure skin-care protocol
Route: Topical
Study duration: Post-treatment recovery period
Source: PMID 16847171 ↗
Product-specific research protocol; not a general dosing recommendation.
COMMUNITY DISCUSSION
Anecdotal injectable pattern · topical products varyWhat people commonly discuss
STARTING APPROACHES
Topical use is usually discussed by product strength and directions. Injectable discussions often begin around 1 mg per day, but no human dose-finding study validates that starting amount.
DURATION / CYCLES
Four-to-eight-week topical or injected courses are commonly described. Formulation, route and absorbed exposure are not interchangeable.
MAINTENANCE DISCUSSION
Intermittent topical use is widely discussed; there is no validated injectable maintenance dose, cycle or break interval.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
COMMUNITY-REPORTED PRACTICEInjection patterns people commonly discussPopular uses · route · site discussion · timing · durationLimited anecdotal consensus
Skin qualityHair and scalp interestWound or tissue-repair interest
ROUTE PEOPLE DISCUSS
Topical use is much more commonly supported and discussed. Injectable subcutaneous use also appears in peptide communities but is less established.
INJECTION-SITE DISCUSSION
When injectable use is discussed, routine subcutaneous sites are more typical than targeted injection into skin, scalp or injured tissue. Evidence for a local injection advantage is lacking.
TIMING PEOPLE DISCUSS
No consistent injection timing pattern has strong support; community discussion tends to focus more on repeated exposure than a particular time of day.
DURATION / CYCLE DISCUSSION
Multi-week courses are discussed, but injectable GHK-Cu lacks a validated human dosing framework for cosmetic or repair uses.
What the evidence supports
Much of the stronger human interest in GHK-Cu relates to topical or local skin products. Injectable community use should not be assumed to share the same evidence base.
Community reports describe what people say they do; they are not instructions, validated protocols, or evidence that a particular injection site or timing improves outcomes.VIAL MATHSSee a worked GHK-Cu example
Calculation example only. The amount below demonstrates the maths; it does not choose a dose or a preparation method.
- Amount in the vial
- 50 mg
- Final liquid volume
- 3 mL
- Example amount
- 1 mg
- Find the concentration50 mg ÷ 3 mL = 16.667 mg/mL
- Convert the amount to liquid volume1 mg ÷ concentration = 0.06 mL
- Read the U-100 volume marking0.06 mL × 100 = 6 U-100 units
The calculation uses the full concentration before rounding the display. U-100 markings measure volume; they are different from a medicine’s international units (IU). Different vial contents or liquid volumes require a new calculation.
Arithmetic vial yield50 amounts of 1 mg, before handling losses or discard limits. This is a quantity estimate, not a shelf-life estimate.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Topical and injectable GHK-Cu are different safety questions
What the current evidence saysTopical products may cause irritation or sensitivity and differ in concentration and delivery. Human evidence does not define the pharmacokinetics, systemic copper exposure or longer-term safety of commonly discussed injections.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
A worsening wound, spreading redness, fever or a severe skin reaction needs medical assessment rather than continued experimentation.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
5 sourcesSources used on this profile
Peer-reviewed human studyEffects of topical copper tripeptide complex on CO2 laser-resurfaced skinPubMed ↗Original publicationEffects of topical copper tripeptide complex on CO2 laser-resurfaced skinJournal / DOI ↗Mechanistic laboratory researchStimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex GHK-CuPubMed ↗Original publicationStimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex GHK-CuJournal / DOI ↗Peer-reviewed reviewTopically applied GHK as an anti-wrinkle peptide: advantages, problems and prospectivePubMed ↗
CURRENT STATUS
How to interpret its position today
No established systemic treatment protocol
Published human work is mainly topical and formulation-specific. It does not establish an authorised injectable GHK-Cu treatment schedule.
Topical clinical study · PubMed ↗Route and formulation matter
Cosmetic serum, wound-care formulation and injectable product cannot be treated as equivalent exposures.
Topical evidence review · PubMed ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.